Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin beta-cell dynamics study in South Asian adults at risk for type 2 diabetes
NL-OMON43940Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prediabetes and impaired fasting glucose (IFG) comparing Vildagliptin with Placebo (2 arms). Primary endpoint: Beta-cell granule and insulin synthesis capacity. Started May 2014; status: active, not recruiting.
02
Drugs
vildagliptin
03
Conditions
prediabetesimpaired fasting glucose (IFG)
Beyond the preview
Go deeper on NL-OMON43940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43940.